Cypherpunk Technologies (NASDAQ:CYPH) Releases Quarterly Earnings Results, Misses Expectations By $0.42 EPS

Cypherpunk Technologies (NASDAQ:CYPH) announced its earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.42), FiscalAI reports.

Cypherpunk Technologies Stock Performance

Shares of NASDAQ:CYPH traded up $0.16 during midday trading on Thursday, hitting $1.20. The company’s stock had a trading volume of 5,738,842 shares, compared to its average volume of 3,743,656. The business’s 50 day simple moving average is $0.83 and its 200 day simple moving average is $0.99. The company has a market cap of $117.22 million, a P/E ratio of 17.14 and a beta of -0.09. Cypherpunk Technologies has a 12-month low of $0.23 and a 12-month high of $3.70.

Hedge Funds Weigh In On Cypherpunk Technologies

A number of institutional investors have recently bought and sold shares of CYPH. Acadian Asset Management LLC raised its stake in Cypherpunk Technologies by 470.4% during the first quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock worth $389,000 after purchasing an additional 1,056,047 shares during the period. Geode Capital Management LLC purchased a new position in Cypherpunk Technologies during the fourth quarter worth about $615,000. State Street Corp purchased a new position in Cypherpunk Technologies during the fourth quarter worth about $163,000. HighTower Advisors LLC purchased a new position in Cypherpunk Technologies during the fourth quarter worth about $59,000. Finally, LPL Financial LLC purchased a new position in Cypherpunk Technologies during the fourth quarter worth about $38,000. 30.46% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Cypherpunk Technologies from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, April 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.